samedan logo
 
 
 
spacer
home > ebr > winter 2003 > the future of biomanufacturing
PUBLICATIONS
European Biopharmaceutical Review

The Future of Biomanufacturing

In my previous article, I reviewed the recent history of biopharmaceutical manufacturing, and the factors that have driven the industry to be the size and shape that it is today. In this article, I will be looking at the emerging trends and technologies, and considering the influence that they will have on biopharmaceutical manufacturing in the future.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Sharon Grimster, Director of Westerly Projects Ltd

Sharon Grimster started her career working on clinical trials at Guys Hospital Medical School in London. She then moved to Celltech, working in research for four years prior to taking up various management positions within contract manufacturing. Sharon subsequently managed preclinical and clinical development programmes for both new chemical entities and biological entities. Following the mergers with Chiroscience and Medeva, Sharon became Head of Biologics Manufacturing Development. She left Celltech in 2002 and is now a Director of Westerly Projects Ltd, a consultancy company offering development services to the biopharmaceutical industry globally.

spacer
Sharon Grimster
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera and Noble announce collaboration to support patients who self-administer medication

Nemera is excited to leverage the new collaboration to expand end-to- end offering of the parenteral franchise and increase patient onboarding through safer multi-use training devices
More info >>

White Papers

The BioPharmaSpec Approach”: Mass Spectrometry Based Host Cell Protein Identification and Quantitation

BioPharmaSpec

1. Introduction As part of the development of any biopharmaceutical product, the impurities present must be examined, minimized and where possible characterized (1). These impurities fall into two broad categories: product-related impurities (derived specifically from the drug product itself) and process-related impurities (derived from material associated with the production, processing or purification of the sample). Host cell proteins (HCPs) are process-related impurities that require specific analysis due to the multitude of naturally occurring proteins expressed in the production cell line.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement